Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Thoracic Malignancies
•
Medical Oncology
Would you use combination of weekly low dose carboplatin and Taxol in patient with small cell lung cancer with poor performance status or cytopenia?
Related Questions
What is the preferred concurrent chemotherapy regimen for limited stage small cell lung cancer with severe reaction to etoposide?
How often, if ever, do patients with initially negative targetable mutation workup become positive later in recurrent lung cancer?
What treatment options would you consider for a patient with stage IV NSCLC harboring a KRAS-G12A mutation who has progressed after chemoimmunotherapy and prefers to avoid additional chemotherapy?
In cases where EGFR NSCLC has transformed into small-cell lung cancer after treatment with Osimertinib, and with no CNS involvement, is it advisable to continue osimertinib alongside chemotherapy?
Did NRG LU004 demonstrate safety with hypofractionated lung radiation and concurrent ICI?
Would you offer consolidative durvalumab after chemoRT for an isolated mediastinal recurrence of NSCLC that occurred during adjuvant pembrolizumab given for the initial lung cancer?
What is your approach for an RA patient with lung cancer who is starting immunotherapy?
Would you use Razor Genomics RiskReveal molecular testing results to guide making recommendations for surgical adjuvant chemotherapy for Stage IA,IB & II non-squamous NSCLCA ?
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
